Skip to main content

Advertisement

Table 3 Supplied amounts of Pt and Pt, As and Se in 24-h urine results for the group patients treated with Pt-based drugs and control group treated without Pt-based drug and the baseline group (a)

From: Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs

Groups Type of cancer Parameter PtSupp(mg) Pt (μg) Se (μg) As (ng)
Cisplatin (Group 1) Lung X 163.0 35.3 3.62 127.0
Med 156.0 28.2 1.28 23.5
DS 66.6 25.9 6.45 267.0
n 32 32 24 21
Min 39.1 3.94 0.208 1.88
Max 263.0 90.4 22.0 1180.0
Cisplatin (Group 2) Other X 174.0 40.1 1.35 216.0
Med 120.0 32.5 1.22 71.0
DS 324.0 36.1 0.717 424.0
n 47 47 36 31
Min 31.6 0.760 0.354 18.8
Max 2297.0 175.0 2.84 2300.0
Carboplatin (Group 3) Other X 695.0 262.0 1.59 40.8
Med a a a a
DS 189.0 201.0 0.711 46.9
n 11 11 9 6
Min 433.0 9.80 0.516 2.53
Max 917.0 680.0 2.52 121.0
Control 1 (b) (Group 4) Other X    1.77 62.0
Med    a a
DS    1.14 59.4
n    7 2
Min    0.333 20.0
Max    3.29 104.0
Control 2 (c) (Group 5) Lung and other X    1.47 48.2
   Med    a a
   DS    0.58 1.56
   n    9 2
   Min    0.45 47.1
   Max    2.16 49.3
  1. Amounts of supplied Pt and Pt, As and Se in 24-h urine samples.
  2. Supp, Supplied; X, mean; Med, Median; SD, Standard deviation; n, number of cases; Min, Minimum value; Max, Maximum value; (a) due the small number of cases, the median values were not reported; (b) non platinum drugs treatment; (c) patients without chemotherapy (two gastric cancer, two bladder cancer and five lung cancer).